Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. reduced its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 73.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 95,383 shares of the company's stock after selling 263,562 shares during the period. Point72 Asset Management L.P. owned approximately 0.21% of Y-mAbs Therapeutics worth $1,254,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in YMAB. Price T Rowe Associates Inc. MD boosted its holdings in shares of Y-mAbs Therapeutics by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company's stock valued at $345,000 after acquiring an additional 1,657 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Y-mAbs Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company's stock worth $993,000 after buying an additional 2,760 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics during the third quarter worth about $44,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock worth $113,000 after purchasing an additional 3,416 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in Y-mAbs Therapeutics by 4.2% in the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company's stock valued at $1,084,000 after acquiring an additional 3,589 shares in the last quarter. Institutional investors own 70.85% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on YMAB. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an "outperform" rating and a $23.00 price objective on the stock. Canaccord Genuity Group restated a "buy" rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a "strong-buy" rating in a research report on Tuesday, August 13th. Wedbush restated an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Finally, Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $17.00 target price on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $20.89.

Y-mAbs Therapeutics Stock Performance

YMAB stock traded down $0.08 during trading on Wednesday, hitting $10.20. The stock had a trading volume of 88,730 shares, compared to its average volume of 323,917. The company's 50 day moving average price is $13.12 and its two-hundred day moving average price is $12.73. Y-mAbs Therapeutics, Inc. has a 1-year low of $6.09 and a 1-year high of $20.90. The stock has a market cap of $456.86 million, a price-to-earnings ratio of -19.04 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same period in the prior year, the business posted ($0.18) earnings per share. As a group, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Thomas Gad sold 30,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the transaction, the insider now directly owns 67,681 shares of the company's stock, valued at approximately $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.50% of the company's stock.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.